Qiagen N.V. (QIA.DE)

38,17 -0,41 (-1,05%) In data: 01:20PM CEST. Mercato aperto.

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 5.191

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thierry Bernard	CEO, MD & Member of Management Board	1,86M	N/D	1965
Dr. Roland Sackers	CFO, MD & Member of Management Board	995,32k	N/D	1969
Mr. Antonio Santos	Senior VP & Head of Global Operations	N/D	N/D	N/D
Mr. John Gilardi	Vice President of Corporate Communications & Investor Relations	N/D	N/D	N/D
Ms. Stephany Foster	Senior VP & Head of Human Resources	N/D	N/D	1979
Dr. Thomas Schweins	Senior Vice President of Life Science Business Area	N/D	N/D	N/D
Dr. Thomas Theuringer	Senior Director & Head of External Communications	N/D	N/D	N/D
Mr. Jean-Pascal Viola	Senior VP & Head of Molecular Diagnostics Business Area	N/D	N/D	N/D
Dr. Jonathan G. Sheldon Ph.D.	Senior Vice President of Qiagen Digital Insights Business Area	N/D	N/D	1972

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Governance aziendale

L'ISS Governance QualityScore di Qiagen N.V. al 1 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 3; diritti degli azionisti: 5; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.